Vélez AG, Cisneros VB

Language: Spanish
References: 79
Page: 27-38
PDF size: 323.07 Kb.

ABSTRACT

In general, human muscular dystrophies are caused by mutations in genes encoding for key proteins of the muscular tissue. A specific group of muscular dystrophies is related to mutations in genes encoding for members of the dystrophin-associated protein complex (DAPC). The DAPC links the extracellular matrix with the actin-based cytoskeleton, conferring thereby stability to the sarcolemma during cycles of muscular contraction/relaxation. A pivotal component of this assembly is dystroglycan, a protein encoded by the DAG1 gene, which is post-translationally processed into two subunits; α- and β-dystroglycan. α-dystroglycan (α-DG) is an extracellular protein that interacts with the extracellular protein laminin, while β-dystroglycan (β-DG) is a transmembranal protein that associates with both α-DG and actin. Therefore, α- and β-DG communicate the extracellular matrix with the actin-based cytoskeleton. α-DG requires to be glycosylated to properly interact with laminin, and such posttranslational modification has biological relevance because a series of muscular dystrophies called «dystroglycanopathies» are caused by defective α-DG glycosylation. Primary dystroglycanopathies are due to homozygous mutations in the DAG1 gene, while secondary dystroglycanopathies are caused by mutations in at least 15 different genes involved in the α-DG glycosylation pathway. The most characterized dystroglycanopathies include the Walker-Warburg syndrome, muscle-eye-brain disease, congenital muscular dystrophies 1C and 1D, and limb-girdle muscular dystrophy. In this review, we describe the clinical aspects of the different dystroglycanopatheis and present an updated view of the genetic and molecular mechanisms underlying these pathologies. Finally, we describe the animal models and therapeutic strategies designed to fight dystroglycanopathies.

REFERENCES

1. Costanza L, Moggio M. Muscular dystrophies: histology, immunohistochemistry, molecular genetics and management. Curr Pharm Des. 2009; 16 (8): 978-987.

2. Sandona D, Betto R. Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects. Expert Rev Mol Med. 2009; 11: e28.

3. Yoshida M et al. Dissociation of the complex of dystrophin and its associated proteins into several unique groups by n-octyl beta-D-glucoside. Eur J Biochem. 1994; 222 (3): 1055-1061.

4. Ehmsen J, Poon E, Davies. The dystrophin-associated protein complex. J Cell Sci. 2002; 115 (Pt 14): 2801-2083.

5. Sweeney HL, Barton ER. The dystrophin-associated glycoprotein complex: what parts can you do without? Proc Natl Acad Sci USA. 2000; 97 (25): 13464-13466.

6. Ervasti JM, Sonnemann KJ. Biology of the striated muscle dystrophin-glycoprotein complex. Int Rev Cytol. 2008; 265: 191-225.

7. Daniele N, Richard I, Bartoli M. Ins and outs of therapy in limb girdle muscular dystrophies. Int J Biochem Cell Biol. 2007; 39 (9): 1608-1624.

8. Bozzi M et al. Enzymatic processing of beta-dystroglycan recombinant ectodomain by MMP-9: identification of the main cleavage site. IUBMB Life. 2009; 61 (12): 1143-1152.

9. Ervasti JM, Campbell KP. Membrane organization of the dystrophin-glycoprotein complex. Cell. 1991; 66 (6): 1121-1131.

10. Ibraghimov-Beskrovnaya O et al. Human dystroglycan: skeletal muscle cDNA, genomic structure, origin of tissue specific isoforms and chromosomal localization. Hum Mol Genet. 1993; 2 (10): 1651-1657.

11. Holt KH et al. Biosynthesis of dystroglycan: processing of a precursor propeptide. FEBS Lett. 2000; 468 (1): 79-83.

12. Talts JF et al. Binding of the G domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides, alpha-dystroglycan and several extracellular matrix proteins. Embo J. 1999; 18 (4): 863-870.

13. Chung W, Campanelli JT, WW and EF hand domains of dystrophin-family proteins mediate dystroglycan binding. Mol Cell Biol Res Commun. 1999; 2 (3): 162-171.

14. Sotgia F et al. Caveolin-3 directly interacts with the C-terminal tail of beta-dystroglycan. Identification of a central WW-like domain within caveolin family members. J Biol Chem. 2000; 275 (48): 38048-38058.

15. Lara-Chacon B et al. Characterization of an importin alpha/beta-recognized nuclear localization signal in beta-dystroglycan. J Cell Biochem. 2010; 110 (3): 706-717.

16. Spence HJ et al. Ezrin-dependent regulation of the actin cytoskeleton by beta-dystroglycan. Hum Mol Genet. 2004; 13 (15): 1657-1668.

17. Bozzi M et al. Functional diversity of dystroglycan. Matrix Biol. 2009; 28 (4): 179-187.

18. Martinez-Vieyra IA et al. A role for beta-dystroglycan in the organization and structure of the nucleus in myoblasts. Biochim Biophys Acta. 2013; 1833 (3): 698-711.

19. Williamson RA et al. Dystroglycan is essential for early embryonic development: disruption of Reichert’s membrane in Dag1-null mice. Hum Mol Genet. 1997; 6 (6): 831-841.

20. Endo T. Glycobiology of alpha-dystroglycan and muscular dystrophy. J Biochem. 2015; 157 (1): 1-12.

21. Michele DE, Campbell KP. Dystrophin-glycoprotein complex: post-translational processing and dystroglycan function. J Biol Chem. 2003; 278 (18): 15457-15460.

22. Akasaka-Manya K et al. Physical and functional association of human protein O-mannosyltransferases 1 and 2. J Biol Chem. 2006; 281 (28): 19339-19345.

23. Jurado LA, Coloma A, Cruces J. Identification of a human homolog of the Drosophila rotated abdomen gene (POMT1) encoding a putative protein O-mannosyl-transferase, and assignment to human chromosome 9q34.1. Genomics. 1999; 58 (2): 171-180.

24. Takahashi S et al. A new beta-1, 2-N-acetylglucosaminyltransferase that may play a role in the biosynthesis of mammalian O-mannosyl glycans. Glycobiology. 2001; 11 (1): 37-45.

25. Peyrard M et al. The human LARGE gene from 22q12.3-q13.1 is a new, distinct member of the glycosyltransferase gene family. Proc Natl Acad Sci USA. 1999; 96 (2): 598-603.

26. Kanagawa M et al. Molecular recognition by LARGE is essential for expression of functional dystroglycan. Cell. 2004; 117 (7): 953-964.

27. Aravind L, Koonin EV. The fukutin protein family –predicted enzymes modifying cell-surface molecules. Curr Biol. 1999; 9 (22): R836-R837.

28. Denecke J, Kranz C. Hypoglycosylation due to dolichol metabolism defects. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2009; 1792 (9): 888-895.

29. Vuillaumier-Barrot S et al. Identification of mutations in TMEM5 and ISPD as a cause of severe cobblestone lissencephaly. Am J Hum Genet. 2012; 91 (6): 1135-1143.

30. Barresi R, Campbell KP. Dystroglycan: from biosynthesis to pathogenesis of human disease. J Cell Sci. 2006; 119 (Pt 2): 199-207.

31. Muntoni F et al. Muscular dystrophies due to glycosylation defects: diagnosis and therapeutic strategies. Curr Opin Neurol. 2011; 24 (5): 437-442.

32. Hewitt JE. Abnormal glycosylation of dystroglycan in human genetic disease. Biochim Biophys Acta. 2009; 1792 (9): 853-861.

33. Beltran-Valero de Bernabe D et al. Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg syndrome. Am J Hum Genet. 2002; 71 (5): 1033-1043.

34. Hafner P et al. Skeletal muscle MRI of the lower limbs in congenital muscular dystrophy patients with novel POMT1 and POMT2 mutations. Neuromuscul Disord. 2014; 24 (4): 321-324.

35. Van Reeuwijk J et al. POMT2 mutations cause alpha-dystroglycan hypoglycosylation and Walker-Warburg syndrome. J Med Genet. 2005; 42 (12): 907-912.

36. Yoshida A et al. Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev Cell. 2001; 1 (5): 717-724.

37. Raducu M et al. Promoter alteration causes transcriptional repression of the POMGNT1 gene in limb-girdle muscular dystrophy type 2O. Eur J Hum Genet. 2012; 20 (9): 945-952.

38. Diesen C et al. POMGnT1 mutation and phenotypic spectrum in muscle-eye-brain disease. J Med Genet. 2004; 41 (10): e115.

39. Kobayashi K et al. An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature. 1998; 394 (6691): 388-392.

40. De Bernabe DB et al. A homozygous nonsense mutation in the fukutin gene causes a Walker-Warburg syndrome phenotype. J Med Genet. 2003; 40 (11): 845-848.

41. Riisager M et al. A new mutation of the fukutin gene causing late-onset limb girdle muscular dystrophy. Neuromuscul Disord. 2013; 23 (7): 562-567.

42. Brockington M et al. Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan. Am J Hum Genet. 2001; 69 (6): 1198-1209.

43. Yamamoto LU et al. Muscle protein alterations in LGMD2I patients with different mutations in the fukutin-related protein gene. J Histochem Cytochem. 2008; 56 (11): 995-1001.

44. Beltran-Valero de Bernabé D et al. Mutations in the FKRP gene can cause muscle-eye-brain disease and Walker-Warburg syndrome. J Med Genet. 2004; 41 (5): e61.

45. Grewal PK et al. Characterization of the LARGE family of putative glycosyltransferases associated with dystroglycanopathies. Glycobiology. 2005; 15 (10): 912-923.

46. Manzini MC et al. Exome sequencing and functional validation in zebrafish identify GTDC2 mutations as a cause of Walker-Warburg syndrome. Am J Hum Genet. 2012; 91 (3): 541-547.

47. Shaheen R et al. A truncating mutation in B3GNT1 causes severe Walker-Warburg syndrome. Neurogenetics. 2013; 14 (3-4): 243-245.

48. Buysse K et al. Missense mutations in beta-1,3-N-acetylglucosaminyltransferase 1 (B3GNT1) cause Walker-Warburg syndrome. Hum Mol Genet. 2013; 22 (9): 1746-1754.

49. Carss KJ et al. Mutations in GDP-mannose pyrophosphorylase B cause congenital and limb-girdle muscular dystrophies associated with hypoglycosylation of alpha-dystroglycan. Am J Hum Genet. 2013; 93 (1): 29-41.

50. Roscioli T et al. Mutations in ISPD cause Walker-Warburg syndrome and defective glycosylation of alpha-dystroglycan. Nat Genet. 2012; 44 (5): 581-585.

51. Yang AC et al. Congenital disorder of glycosylation due to DPM1 mutations presenting with dystroglycanopathy-type congenital muscular dystrophy. Mol Genet Metab. 2013; 110 (3): 345-351.

52. Barone R et al. DPM2-CDG: a muscular dystrophy-dystroglycanopathy syndrome with severe epilepsy. Ann Neurol. 2012; 72 (4): 550-558.

53. Lefeber DJ et al. Deficiency of Dol-P-Man synthase subunit DPM3 bridges the congenital disorders of glycosylation with the dystroglycanopathies. Am J Hum Genet. 2009; 85 (1): 76-86.

54. Lefeber DJ et al. Autosomal recessive dilated cardiomyopathy due to DOLK mutations results from abnormal dystroglycan O-mannosylation. PLoS Genet. 2011; 7 (12): e1002427.

55. Hara Y et al. A dystroglycan mutation associated with limb-girdle muscular dystrophy. N Engl J Med. 2011; 364 (10): 939-946.

56. Riemersma M et al. Absence of alpha- and beta-dystroglycan is associated with Walker-Warburg syndrome. Neurology. 2015; 84 (21): 2177-2182.

57. Geis T et al. Homozygous dystroglycan mutation associated with a novel muscle-eye-brain disease-like phenotype with multicystic leucodystrophy. Neurogenetics. 2013; 14 (3-4): 205-213.

58. Cohn RD. Dystroglycan: important player in skeletal muscle and beyond. Neuromuscul Disord. 2005; 15 (3): 207-217.

59. Godfrey C et al. Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. Brain. 2007; 130 (Pt 10): 2725-2735.

60. Trkova M et al. ISPD gene homozygous deletion identified by SNP array confirms prenatal manifestation of Walker-Warburg syndrome. Eur J Med Genet. 2015; 58 (8): 372-375.

61. Taniguchi K et al. Worldwide distribution and broader clinical spectrum of muscle-eye-brain disease. Hum Mol Genet. 2003; 12 (5): 527-534.

62. Toda T et al. The Fukuyama congenital muscular dystrophy story. Neuromuscul Disord. 2000; 10 (3): 153-159.

63. Silan F et al. A new mutation of the fukutin gene in a non-Japanese patient. Ann Neurol. 2003; 53 (3): 392-396.

64. Longman C et al. Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan. Hum Mol Genet. 2003; 12 (21): 2853-2861.

65. Nigro V, Aurino S, Piluso G. Limb girdle muscular dystrophies: update on genetic diagnosis and therapeutic approaches. Curr Opin Neurol. 2011; 24 (5): 429-436.

66. Godfrey C et al. Dystroglycanopathies: coming into focus. Curr Opin Genet Dev. 2011; 21 (3): 278-285.

67. Cohn RD et al. Disruption of DAG1 in differentiated skeletal muscle reveals a role for dystroglycan in muscle regeneration. Cell. 2002; 110 (5): 639-648.

68. Moore SA et al. Deletion of brain dystroglycan recapitulates aspects of congenital muscular dystrophy. Nature. 2002; 418 (6896): 422-425.

69. Kurahashi H et al. Basement membrane fragility underlies embryonic lethality in fukutin-null mice. Neurobiol Dis. 2005; 19 (1-2): 208-217.

70. Willer T et al. Targeted disruption of the Walker-Warburg syndrome gene Pomt1 in mouse results in embryonic lethality. Proc Natl Acad Sci USA. 2004; 101 (39): 14126-14131.

71. Takeda S et al. Fukutin is required for maintenance of muscle integrity, cortical histiogenesis and normal eye development. Hum Mol Genet. 2003; 12 (12): 1449-1459.

72. Holzfeind PJ et al. Skeletal, cardiac and tongue muscle pathology, defective retinal transmission, and neuronal migration defects in the Large(myd) mouse defines a natural model for glycosylation-deficient muscle-eye-brain disorders. Hum Mol Genet. 2002; 11 (21): 2673-2687.

73. Liu J et al. A genetic model for muscle-eye-brain disease in mice lacking protein O-mannose 1, 2-N-acetylglucosaminyltransferase (POMGnT1). Mech Dev. 2006; 123 (3): 228-240.

74. Bassett DI, Currie PD. The zebrafish as a model for muscular dystrophy and congenital myopathy. Hum Mol Genet. 2003; 12 Spec 2: R265-270.

75. Gupta V et al. The zebrafish dag1 mutant: a novel genetic model for dystroglycanopathies. Hum Mol Genet. 2011; 20 (9): 1712-1725.

76. Kawahara G et al. Zebrafish models for human FKRP muscular dystrophies. Hum Mol Genet. 2010; 19 (4): 623-633.

77. Inamori K et al. Dystroglycan function requires xylosyl- and glucuronyltransferase activities of LARGE. Science. 2012; 335 (6064): 93-96.

78. Barresi R et al. LARGE can functionally bypass alpha-dystroglycan glycosylation defects in distinct congenital muscular dystrophies. Nat Med. 2004; 10 (7): 696-703.

79. Hewitt JE. LARGE enzyme activity deciphered: a new therapeutic target for muscular dystrophies. Genome Med. 2012; 4 (3): 23.